Background: Thrombocytopenia is commonly noted in critically ill patients resulting from various etiologies, including but not limited to sepsis, shock, or medications. Critically ill patients receiving renal replacement therapy (RRT) may be on concomitant heparin, raising suspicion for heparin-induced thrombocytopenia (HIT). However, literature suggests that thrombocytopenia may occur due to continuous renal replacement therapy (CRRT) itself. The primary objective of this study is to evaluate the incidence of thrombocytopenia in patients receiving both continuous renal replacement therapy and prolonged intermittent renal replacement therapy (PIRRT). Methods: This retrospective observational analysis aimed to evaluate thrombocytopenia in patients receiving CRRT, PIRRT, or both in a single admission. Data was gathered from patients receiving extended RRT while admitted to a single institution from November 2021 to October 2023. The primary outcome was incidence of thrombocytopenia after initiating extended RRT, as defined by a reduction in platelet count to less than 150 × 109/L in a previously nonthrombocytopenic patient. Results: Of the patients included in this study undergoing extended RRT, 32/51 (62.8%) experienced thrombocytopenia either during RRT or within 24 hours of RRT completion. The mean baseline platelet count was 250.7 × 109/L and the mean percent change in platelet count was a decrease of 43.5%. Conclusion: CRRT and PIRRT were associated with a high incidence of new onset thrombocytopenia in patients admitted to the ICU.
References
[1]
Jinna, S. and Khandhar, P.B. (2023) Thrombocytopenia. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK542208
[2]
Williamson, D.R., Albert, M., Heels-Ansdell, D., Arnold, D.M., Lauzier, F., Zarychanski, R., et al. (2013) Thrombocytopenia in Critically Ill Patients Receiving Thromboprophylaxis: Frequency, Risk Factors, and Outcomes. Chest, 144, 1207-1215. https://doi.org/10.1378/chest.13-0121
[3]
Droege, C.A., Ernst, N.E., Messinger, N.J., Burns, A.M. and Mueller, E.W. (2018) Evaluation of Thrombocytopenia in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Annals of Pharmacotherapy, 52, 1204-1210. https://doi.org/10.1177/1060028018779200
[4]
Zarychanski, R. and Houston, D.S. (2017) Assessing Thrombocytopenia in the Intensive Care Unit: The Past, Present, and Future. Hematology, 2017, 660-666. https://doi.org/10.1182/asheducation-2017.1.660
[5]
Teixeira, J.P., Hiremath, S., Kabli, A.O., Rewa, O.G. and Clark, E.G. (2025) Continuous Kidney Replacement Therapies: Core Curriculum 2025. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2024.09.015
[6]
Clark, E.G. and Vijayan, A. (2023) How I Prescribe Prolonged Intermittent Renal Replacement Therapy. Critical Care, 27, Article No. 88. https://doi.org/10.1186/s13054-023-04389-7
[7]
Nash, D.M., Przech, S., Wald, R. and O'Reilly, D. (2017) Systematic Review and Meta-Analysis of Renal Replacement Therapy Modalities for Acute Kidney Injury in the Intensive Care Unit. Journal of Critical Care, 41, 138-144. https://doi.org/10.1016/j.jcrc.2017.05.002
[8]
Outset Inc (2025) Tablo® for Nephrologists. https://www.outsetmedical.com/providers/nephrologists/
[9]
Nichols, T.G., Doman, D., Mullen, S., Ramaiyah, S., Rowe, S., D’Alessandri-Silva, C.J., et al. (2024) Intensive Care Unit Improves Dialysis Care Quality While Reducing Costs. Journal of Medical Economics, 27, 797-799. https://doi.org/10.1080/13696998.2024.2357038
[10]
Posadas, M.A., Hahn, D., Schleuter, W. and Paparello, J. (2011) Thrombocytopenia Associated with Dialysis Treatments. Hemodialysis International, 15, 416-423. https://doi.org/10.1111/j.1542-4758.2011.00561.x
[11]
Cuker, A., Arepally, G.M., Chong, B.H., Cines, D.B., Greinacher, A., Gruel, Y., et al. (2018) American Society of Hematology 2018 Guidelines for Management of Venous Thromboembolism: Heparin-Induced Thrombocytopenia. Blood Advances, 2, 3360-3392. https://doi.org/10.1182/bloodadvances.2018024489
[12]
Smythe, M.A., Koerber, J.M., Fitzgerald, M. and Mattson, J.C. (2008) The Financial Impact of Heparin-Induced Thrombocytopenia. Chest, 134, 568-573. https://doi.org/10.1378/chest.08-0120
[13]
Lo, G.K., Juhl, D., Warkentin, T.E., Sigouin, C.S., Eichler, P. and Greinacher, A. (2006) Evaluation of Pretest Clinical Score (4 T’s) for the Diagnosis of Heparin-Induced Thrombocytopenia in Two Clinical Settings. Journal of Thrombosis and Haemostasis, 4, 759-765. https://doi.org/10.1111/j.1538-7836.2006.01787.x
[14]
Vatanparast, R., Lantz, S., Ward, K., Crilley, P.A. and Styler, M. (2012) Evaluation of a Pretest Scoring System (4Ts) for the Diagnosis of Heparin-Induced Thrombocytopenia in a University Hospital Setting. Postgraduate Medicine, 124, 36-42. https://doi.org/10.3810/pgm.2012.11.2611
[15]
Wester, J.P.J., Haas, F.J.L.M., Biesma, D.H., Leusink, J.A. and Veth, G. (2004) Thrombosis and Hemorrhage in Heparin-Induced Thrombocytopenia in Seriously Ill Patients. Intensive Care Medicine, 30, 1927-1934. https://doi.org/10.1007/s00134-004-2334-1
[16]
Ferreira, J.A. and Johnson, D.W. (2015) The Incidence of Thrombocytopenia Associated with Continuous Renal Replacement Therapy in Critically Ill Patients. Renal Failure, 37, 1232-1236. https://doi.org/10.3109/0886022x.2015.1057799
[17]
Wu, B., Gong, D., Xu, B., He, Q., Liu, Z. and Ji, D. (2014) Decreased Platelet Count in Patients Receiving Continuous Veno-Venous Hemofiltration: A Single-Center Retrospective Study. PLOS ONE, 9, e97286. https://doi.org/10.1371/journal.pone.0097286
[18]
Kellum, J.A., Aspelin, P., Barsoum, R.S., Burdmann, E.A., Paulo, S., Herzog, C.A., et al. (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements, 2, 89-115.
